The war against the

antimicrobial resistance (AMR)

Since 1928, with the discovery of penicillin by Sir Alexander Fleming, microorganisms have learned to develop mechanisms of drug resistance. Now the world is running out of drugs to fight microorganisms, due to Antimicrobial resistance (AMR).


A global war

The emergence of resistance in many pathogenic microorganisms, particularly bacteria, fungi and viruses as highlighted by the WHO, places the world in urgent need of developing new therapeutic options to effectively combat infections.

 Antibiotic-resistant bacteria will cause 10 million deaths worldwide

Antimicrobial resistance is included in the list of "urgent global health problems" (WHO, 2020)

The increase of antibiotic resistance has always been closely linked to their use, meaning that the antibiotics we use today will contribute to the resistance of tomorrow.


The onset of bacteria resistant to antibiotics, including those of last resort (DoLR), has made it imperative for global healthcare systems to urgently develop new therapeutic options to effectively combat infections.


medical need

The world faces the challenge of finding new entities and structures to develop innovative drugs.

Antimicrobial resistance (AMR) is an urgent global public health threat

According to the WHO, the desperate use of antibiotics during the COVID-19 pandemic has exponentially increased, placing us at levels of antimicrobial resistance that would be expected by 2030.

The development of new antibiotics to combat the future pandemic of resistant bacteria has become an urgent necessity that we must address.


The total number of deaths resulting from causes related to AMR exceeds the combined death toll of HIV, tuberculosis, and malaria.

The market


Bacterial resistance poses a major problem that currently lacks enough antibiotics and therapeutic drugs

It is estimated that by 2050, the number of deaths due to antimicrobial resistance (AMR) will surpass those caused by cancer (10 million versus 8.2 million). In contrast, according to the Centers for Disease Control and Prevention (CDC), for every antibacterial product in development, there are 100 in the field of oncology.

Hifas biologics has the experience, Know how and capabilities to lever on the potential of the fungi compounds to develop new drugs to solve this market unmet need.


Be part of the company
Fleming would’ve invested in